Aurion Biotech is a company focused on the development of advanced therapies for corneal diseases, aiming to restore vision to patients with corneal blindness. The company is built on a foundation of scientific innovation and is dedicated to advancing the field of ophthalmology through the development of cell-based therapies.

Aurion Biotech

Crespel & Deiters is a manufacturer of wheat-based products, specializing in the production of wheat starches and wheat proteins, providing application-oriented solutions for various industries.

Crespel & Deiters

Vision Biotechnology specializes in developing and manufacturing diagnostic test kits for healthcare professionals to accurately diagnose various diseases. The company incorporates the latest advancements in biotechnology into its products, self-described as elevating healthcare through innovative testing solutions.

Vision Biotechnology

Choice Optical & Surgical focuses on providing eye care services, including comprehensive eye tests and treatments for conditions such as cataracts and glaucoma, as described by the company.

Choice Optical & Surgical

Aurion Biotech is a clinical stage biotech company, developing a transformational platform of advanced therapies to cure blindness. Our first candidate is for the treatment of corneal endothelial disease, and one of the first clinically validated cell therapies for corneal care.

Visionary Venture Fund

Alcon

Petrichor Healthcare Capital Management

Deerfield

Falcon Vision

Flying L Partners

So, THIS happened! Congrats to our fab CEO, Greg Kunst! #EOYUS #EOYMTNWEST

Glad that our CEO Greg Kunst will be speaking at Octane's upcoming Ophthalmology Tech Forum in lovely Newport Beach CA, June 20-21.
#OTF2024 #OphthalmicInnovation #OphthalmicTech

Thanks to Aurion's Nysha Blender, OD, PhD for a fantastic job presenting at ARVO this week in Seattle!

Big milestone: we've completed enrollment in our CLARA trial! https://lnkd.in/gYn-3C-N

Thanks to Ophthalmology Times for this terrific post of Eris Jordan, OD describing progress Aurion Biotech! https://lnkd.in/gcFzd-2f

Delighted and honored that our CEO Greg Kunst a finalist for Entrepreneur of the Year! https://lnkd.in/g2TRCNjE

Metric
Company Name	Aurion Biotech	Crespel & Deiters	Vision Biotechnology	Choice Optical & Surgical
Symbol
MSH ID	COM:AURIONBIOTECH	COM:CRESPELDEITERSGROUP	COM:VISIONBIOTECHNOLOGY	NG:COM:CHOICEOPTICAL
Market	PRIVATE	PRIVATE	PRIVATE	PRIVATE
Sector	Healthcare & Health Services	Consumer Goods	Healthcare & Health Services	Healthcare & Health Services
Industry	Biotechnology	Food Products	Biotechnology	Healthcare
Country	US	DE	US	NG
Stage
Employee Count	70
Website	aurionbiotech.com	crespeldeitersgroup.com	visionbiotechnology.com	choiceoptical.com.ng
LinkedIn	aurion-biotech		visionbiotechnolgy
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic			434
Web Traffic Growth			1.39
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:AURIONBIOTECH

Aurion Biotech

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue